Brain uptake of thiamine-coated nanoparticles.

Recently, a novel nanoparticle (NP) comprised of emulsifying wax and Brij 78 was shown to have significant brain uptake using the in-situ rat brain perfusion technique. To further these studies and to specifically target brain, we have incorporated thiamine as a surface ligand on the nanoparticles. Solid nanoparticles were prepared from oil-in-water microemulsion precursors. Nanoparticles were radiolabeled and a thiamine ligand (thiamine linked to distearoylphosphatidylethanolamine via a polyethylene glycol spacer) was coated on the surface of the nanoparticles. Initial experiments focused on assessing uptake of [3H]nanoparticles with and without thiamine surface ligands. Biodistribution nanoparticle studies were also carried out in BALB/c mice. The results showed: (1) the effectiveness of using microemulsions as precursors to engineer nanoparticles, (2) kinetic modeling for brain uptake of nanoparticles with and without the thiamine surface ligands, and (3) initial data suggesting mechanisms for nanoparticle brain entry. Comparison of NP brain uptake demonstrated that the thiamine-coated nanoparticle associated with the blood-brain barrier (BBB) thiamine transporter and had an increased K(in) between 45 and 120 s (thiamine coated NP 9.8 +/- 1.1 x 10(-3) ml/s/g versus uncoated NPs; 7.0 +/- 0.3 x 10(-3) ml/s/g). It was concluded that the thiamine ligand facilitated binding and/or association with blood-brain barrier thiamine transporters, which may be a viable mechanism for nanoparticle mediated brain drug delivery.

[1]  R. Mumper,et al.  In Situ Blood–Brain Barrier Transport of Nanoparticles , 2003, Pharmaceutical Research.

[2]  David J. Begley,et al.  The Blood-brain Barrier and Drug Delivery to the CNS , 2000 .

[3]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.

[4]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[5]  W. Pardridge,et al.  Drug and Gene Delivery to the Brain The Vascular Route , 2002, Neuron.

[6]  W. Pardridge Brain drug targeting and gene technologies. , 2001, Japanese journal of pharmacology.

[7]  Q. Smith Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. , 1996, Pharmaceutical biotechnology.

[8]  M. Brightman,et al.  Morphology of blood-brain interfaces. , 1977, Experimental eye research.

[9]  S. Rapoport,et al.  An in situ brain perfusion technique to study cerebrovascular transport in the rat. , 1984, The American journal of physiology.

[10]  D D Allen,et al.  Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier , 2002, Drug development and industrial pharmacy.

[11]  R. Mumper,et al.  Gadolinium-Loaded Nanoparticles Engineered from Microemulsion Templates , 2002, Drug development and industrial pharmacy.

[12]  Paul R. Lockman,et al.  In Vivo and in Vitro Assessment of Baseline Blood-Brain Barrier Parameters in the Presence of Novel Nanoparticles , 2003, Pharmaceutical Research.

[13]  Q. Smith,et al.  Characterization of the blood–brain barrier choline transporter using the in situ rat brain perfusion technique , 2001, Journal of neurochemistry.

[14]  R. Mumper,et al.  Specific association of thiamine-coated gadolinium nanoparticles with human breast cancer cells expressing thiamine transporters. , 2003, Bioconjugate chemistry.

[15]  Bernhard A. Sabel,et al.  Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections , 1996, Brain Research.

[16]  G. Vassal,et al.  Poly(ethylene glycol)-Coated Hexadecylcyanoacrylate Nanospheres Display a Combined Effect for Brain Tumor Targeting , 2002, Journal of Pharmacology and Experimental Therapeutics.

[17]  J. Kreuter,et al.  Using Nanoparticles to Target Drugs to the Central Nervous System , 2000 .

[18]  S. Vyas,et al.  Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting. , 2001, Critical reviews in therapeutic drug carrier systems.

[19]  L. Drewes,et al.  Frontiers in Cerebral Vascular Biology: Transport and Its Regulation. Proceedings of CVB '92. Duluth, Minnesota, July 11-13, 1992. , 2012, Advances in experimental medicine and biology.

[20]  J. Greenwood,et al.  Kinetics of thiamine transport across the blood‐brain barrier in the rat. , 1982, The Journal of physiology.

[21]  Q. Smith Drug delivery to brain and the role of carrier-mediated transport. , 1993, Advances in experimental medicine and biology.

[22]  D. A. Kharkevich,et al.  Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. , 1998, Journal of microencapsulation.

[23]  P. Low,et al.  Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[24]  R. Mumper,et al.  Evaluation of blood–brain barrier thiamine efflux using the in situ rat brain perfusion method , 2003, Journal of neurochemistry.